Top Industry Leaders in the Tumor Necrosis Factor Alpha Inhibitors Market
Latest Tumor Necrosis Factor Alpha Inhibitors Companies Updates:
Pfizer: Launch of XELJANZ (tofacitinib) for ankylosing spondylitis treatment shows continued expansion beyond rheumatoid arthritis.
Janssen: Collaborative effort to transform infliximab (Remicade) into an oral capsule for irritable bowel disease showcases the push towards patient-friendly options.
AbbVie: Patent expiry for Humira (adalimumab) in 2023 leads to increased competition from biosimilars, impacting market share.
Emerging players: Companies like Momenta Pharmaceuticals and HanAll Biopharma are entering the market with biosimilar versions of existing TNF-alpha inhibitors, driving down costs.
List of Tumor Necrosis Factor Alpha Inhibitors Key companies in the market:
- AbbVie Inc. (U.S.)
- Ablynx (Belgium)
- ApogenixGmBH (Germany)
- AryoGen Biopharma (U.S.)
- Bionovis (Brazil)
- CASI Pharmaceuticals (U.S.)
- Celltrion Healthcare (South Korea.)
- Celgene Corporation (U.S.)
- Delenex Therapeutics (Switzerland)
- Dexa Medica (Indonesia)
- EPIRUS Biopharmaceuticals (U.S.)
- Janssen Biotech (U.S.)
- GlaxoSmithKline Inc. (U.S.)
- HanAll Biopharma (South Korea.)
- Intas Pharmaceuticals (India)
- LEO Pharma (Denmark)